HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NDI Notifications Take Center Stage In FDA's Evaluation Of DSHEA

Executive Summary

FDA's notice for a May 16 public meeting say it intends to ensure its "regulatory framework is flexible enough to adequately evaluate product safety without unnecessarily restricting innovation." But FDA makes clear adherence with its NDI notification requirement is focus of the spurring improvement in VMS product industry's overall compliance with regulatory framework established by DSHEA.


Related Content

FDA Debuts List For Rapidly Announcing Noncompliant Ingredients In Supplements
DoJ Prosecutions: USPlabs Guilty, DMBA Firm Indicted From FDA Investigations
Modernizing FDA's Supplement Industry Regulation Mapped Out In Five-Point Plan
FDA Could Stick With Current Advice On NDI Notifications, Old Ingredient Evidence
Supplement GMP Inspections Slowing As FDA Makes 'Potential' Data Useful
DMAA, Other Stimulants Cast Shadow Over FDA Supplement Regulation – Study





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts